GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:05 2024-04-15 am EDT			5-day change	1st Jan Change
1,644 ^GBX	0.00%		+1.45%	+13.33%

08:41am	GSK Says FDA Accepts GSK Meningitis Vaccine Candidate File	RE
08:25am	US FDA Accepts GSK's Meningococcal Disease Vaccine Candidate for Regulatory Review	MT

GSK : UBS keeps a Sell rating

February 01, 2023 at 06:26 am EST

Michael Leuchten from UBS retains his negative opinion on the stock with a Sell rating. The target price is unchanged at GBX 1245.

Latest news about GSK plc

GSK Says FDA Accepts GSK Meningitis Vaccine Candidate File	02:41am	RE
US FDA Accepts GSK's Meningococcal Disease Vaccine Candidate for Regulatory Review	02:25am	MT
Pfizer RSV shot meets goals in trial of high-risk adults under age 60	Apr. 09	RE
GSK : Barclays sticks Neutral	Apr. 08	ZD
Barclays Lifts GSK PT, Maintains Equalweight Rating	Apr. 08	MT
Wizz Air raised; HSBC cuts Rentokil to 'hold'	Apr. 08	AN
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers	Apr. 04	MT
GSK : Barclays reiterates its Neutral rating	Apr. 04	ZD
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	Apr. 04	MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	Apr. 04	MT
Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs	Apr. 03	RE
GSK : Berenberg gives a Buy rating	Apr. 03	ZD
GSK : Sell rating from JP Morgan	Mar. 28	ZD
U.S. FDA approves Akebia's anemia drug	Mar. 27	RE
GSK FILES FOR DEBT SHELF; SIZE NOT DISCLOSED - SEC FILING…	Mar. 25	RE
Moderna, Inc. prepares for the post-Covid era	Mar. 25
British Drugmaker GSK to Introduce Price Cap on Inhaled Products from 2025	Mar. 21	MT
GSK to cap out-of-pocket inhaler costs in US	Mar. 20	RE
GSK Announces Cap Of $35 Per Month On U.S. Patient Out-Of-Pocket Costs	Mar. 20	RE
GSK - PROGRAM IS WIDE REACHING AND WILL BE IMPLEMENTED NO LATER…	Mar. 20	RE
GSK ANNOUNCES CAP OF $35 PER MONTH ON U.S. PATIENT OUT-OF-POCKET…	Mar. 20	RE
GSK : Buy rating from Jefferies	Mar. 20	ZD
CAC40: Paris and E-Stoxx50 close at record highs	Mar. 19	CF
Repeat & Correct : Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale -- Update	Mar. 19	DJ
CAC40: in record territory, oil at year's high	Mar. 19	CF

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK PLC : 2023 ended on a strong note; medium- to long-term guidance raised

February 02, 2024 at 09:40 am EST

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.44 GBP

Average target price

20 GBP

Spread / Average Target

+21.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+13.33%	83.67B
ELI LILLY AND COMPANY	+28.79%	676B
NOVO NORDISK A/S	+25.94%	559B
JOHNSON & JOHNSON	-5.84%	356B
MERCK & CO., INC.	+15.75%	320B
ABBVIE INC.	+4.32%	286B
ASTRAZENECA PLC	+4.00%	213B
NOVARTIS AG	+1.92%	207B
ROCHE HOLDING AG	-7.93%	199B
PFIZER, INC.	-10.00%	147B

Other Pharmaceuticals

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

GSK : UBS keeps a Sell rating

Latest news about GSK plc

Chart GSK plc

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for GSK plc

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals